354 related articles for article (PubMed ID: 30995174)
1. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer.
Randall ME; Filiaci V; McMeekin DS; von Gruenigen V; Huang H; Yashar CM; Mannel RS; Kim JW; Salani R; DiSilvestro PA; Burke JJ; Rutherford T; Spirtos NM; Terada K; Anderson PR; Brewster WR; Small W; Aghajanian CA; Miller DS
J Clin Oncol; 2019 Jul; 37(21):1810-1818. PubMed ID: 30995174
[TBL] [Abstract][Full Text] [Related]
2. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of vaginal cuff brachytherapy followed by dose-dense chemotherapy in early stage endometrial cancer patients with enriched, high-intermediate risk factors for recurrence.
Castellano T; John Maxwell IV; Adam Walter J; Thompson S; McMeekin DS; Landrum LM
Gynecol Oncol; 2021 Mar; 160(3):669-673. PubMed ID: 33358492
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors.
Landrum LM; Nugent EK; Zuna RE; Syzek E; Mannel RS; Moore KN; Walker JL; McMeekin DS
Gynecol Oncol; 2014 Jan; 132(1):50-4. PubMed ID: 24219982
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer.
Lupe K; D'Souza DP; Kwon JS; Radwan JS; Harle IA; Hammond JA; Carey MS
Gynecol Oncol; 2009 Jul; 114(1):94-8. PubMed ID: 19406459
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; D'Amico R; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Gribaudo S; Provencher D; Hanzen C; Kruitwagen RF; Smit VTHBM; Singh N; Do V; Lissoni A; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
Lancet Oncol; 2019 Sep; 20(9):1273-1285. PubMed ID: 31345626
[TBL] [Abstract][Full Text] [Related]
7. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
Alektiar KM; Venkatraman E; Chi DS; Barakat RR
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
[TBL] [Abstract][Full Text] [Related]
8. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy.
Murphy KT; Rotmensch J; Yamada SD; Mundt AJ
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1272-6. PubMed ID: 12654437
[TBL] [Abstract][Full Text] [Related]
9. Recurrences and toxicity after adjuvant vaginal brachytherapy in Stage I-II endometrial cancer: A monoinstitutional experience.
Perrucci E; Lancellotta V; Bini V; Zucchetti C; Mariucci C; Montesi G; Saccia S; Palumbo I; Aristei C
Brachytherapy; 2016; 15(2):177-84. PubMed ID: 26727332
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics.
Young MR; Higgins SA; Ratner E; Yu JB; Mani S; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Damast S
Int J Gynecol Cancer; 2015 Mar; 25(3):431-9. PubMed ID: 25621409
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant brachytherapy for FIGO stage I serous or clear cell endometrial cancer.
Jeans EB; Breen WG; Mullikin TC; Looker BA; Mariani A; Keeney GL; Haddock MG; Petersen IA
Int J Gynecol Cancer; 2021 Jun; 31(6):859-867. PubMed ID: 33563642
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; Colombo A; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Carinelli S; Provencher D; Hanzen C; Lutgens LCHW; Smit VTHBM; Singh N; Do V; D'Amico R; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
Lancet Oncol; 2018 Mar; 19(3):295-309. PubMed ID: 29449189
[TBL] [Abstract][Full Text] [Related]
13. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy.
Hochreiter A; Kelly JR; Young MR; Litkouhi B; Black JD; Stromberger C; Higgins S; Schwartz PE; Damast S
Int J Gynecol Cancer; 2020 Jan; 30(1):48-55. PubMed ID: 31722964
[TBL] [Abstract][Full Text] [Related]
14. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma--a prospective randomized study.
Sorbe B; Horvath G; Andersson H; Boman K; Lundgren C; Pettersson B
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1249-55. PubMed ID: 21676554
[TBL] [Abstract][Full Text] [Related]
15. Vaginal brachytherapy alone: an alternative to adjuvant whole pelvis radiation for early stage endometrial cancer.
Jolly S; Vargas C; Kumar T; Weiner S; Brabbins D; Chen P; Floyd W; Martinez AA
Gynecol Oncol; 2005 Jun; 97(3):887-92. PubMed ID: 15943991
[TBL] [Abstract][Full Text] [Related]
16. Single-institutional outcomes of adjuvant brachytherapy for Stage I endometrial cancer-Are outcomes consistent with randomized studies?
Dohopolski MJ; Horne ZD; Gebhardt BJ; Glaser SM; Edwards RP; Kelley JL; Comerci JT; Olawaiye AB; Courtney-Brooks M; Berger JL; Sukumvanich P; Beriwal S
Brachytherapy; 2018; 17(3):564-570. PubMed ID: 29426745
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant Carboplatin and Paclitaxel Chemotherapy Followed by Radiotherapy in High-Risk Endometrial Cancer: A Retrospective Analysis.
Rodrigues da Cunha Colombo Bonadio R; Gondim Meira Velame Azevedo R; Harada G; Cabral Severino da Costa S; Costa Miranda V; de Freitas D; Abdo Filho E; Alves de Oliveira Ferreira P; Gabrielli F; Del Pilar Estevez Diz M
J Glob Oncol; 2018 Sep; 4():1-8. PubMed ID: 30241227
[TBL] [Abstract][Full Text] [Related]
18. Impact of different adjuvant radiotherapy modalities on women with early-stage intermediate- to high-risk endometrial cancer.
Jin M; Hou X; Sun X; Zhang Y; Hu K; Zhang F
Int J Gynecol Cancer; 2019 Oct; 29(8):1264-1270. PubMed ID: 31320487
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors of recurrence following adjuvant vaginal cuff brachytherapy alone for stage I endometrial cancer.
Dunn EF; Geye H; Platta CS; Gondi V; Rose S; Bradley KA; Anderson BM
Gynecol Oncol; 2014 Jun; 133(3):494-8. PubMed ID: 24657301
[TBL] [Abstract][Full Text] [Related]
20. A Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial Cancer.
Hathout L; Wang Y; Wang Q; Vergalasova I; Elshaikh MA; Dimitrova I; Damast S; Li JY; Fields EC; Beriwal S; Keller A; Kidd EA; Usoz M; Jolly S; Jaworski E; Leung EW; Donovan E; Taunk NK; Chino J; Natesan D; Russo AL; Lea JS; Albuquerque KV; Lee LJ
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1423-1431. PubMed ID: 33677053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
